A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease (EMPA-KIDNEY)

Documents

Study protocol

Initial protocol

EMPA-KIDNEY_Protocol_v2p0

Study results

Study results

1245-0137_Synopsis.pdf

Study report

No information provided.

Publications

Study publications

Baigent C, Emberson J, Haynes R, Herrington WG, Judge P, Landray MJ, Mayne KJ, …

EMPA-Kidney Collaborative Group. Empagliflozin in patients with chronic kidney …

Herrington WG, Preiss D, Haynes R, Eynatten M, von Staplin N, Hauske SJ et al. …

"Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial." N…

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.